Olema Pharmaceuticals IncOLMA
Price$8.27

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$204.6MTTM through 30 Jun 2026
Free Cash Flow -$164.9MTTM through 30 Jun 2026

Margins

Current

Returns

-38.5%ROE
-41.2%ROA

Balance Sheet Health

Debt / Equity0.01x
Current Ratio10.88x
Net Debt-$502.3Mnet cash position
Cash & Equivalents$48.6M

Quality Metrics

Altman Z-Score6.51
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Diluted EPS-$2.12TTM
'19'20'21'22'23'24'25
FY2025: $-1.87

Dividend

No dividend

Capital Allocation

R&D Spend$190.2M

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.